Latest news with #ChineseMedicine
Malay Mail
17 hours ago
- Health
- Malay Mail
Hong Kong Baptist University Showcases World-Leading Research in Digital Health & Systems Medicine at THE Global Sustainable Development Congress 2025
HKBU's "Well-being Zone" showcases interdisciplinary global health, with sessions like Tai Chi, Baduanjin, and Mindfulness Karate reflecting its "exercise is medicine" approach to holistic well-being. Interdisciplinary Movement & Mindfulness: Tai Chi, Baduanjin and Mindfulness Karate sessions demonstrated HKBU's "exercise is medicine" philosophy. Tai Chi, Baduanjin and Mindfulness Karate sessions demonstrated HKBU's "exercise is medicine" philosophy. Real-Time Digital Well-being Research: Participants had the unique opportunity to contribute live data for Professor Christy Cheung's pioneering studies, which explore how digital tools can effectively measure mindfulness and enhance overall well-being. Participants had the unique opportunity to contribute live data for Professor Christy Cheung's pioneering studies, which explore how digital tools can effectively measure mindfulness and enhance overall well-being. Expert-Led Talks: Distinguished HKBU academics presented cutting-edge interdisciplinary research. Topics included critical global health trends, advancements in mental well-being, and innovative applications of Chinese Medicine and AI in modern healthcare. Distinguished HKBU academics presented cutting-edge interdisciplinary research. Topics included critical global health trends, advancements in mental well-being, and innovative applications of Chinese Medicine and AI in modern healthcare. Reflection & Rejuvenation Spaces: Thoughtfully curated "chill-out" relaxation areas, massage corners and a juice bar provided spaces for participants to experience a reboot of the body and the mind. HKBU scholars presented cutting-edge research on global health and Chinese Medicine at GSDC 2025. ISTANBUL, TURKEY - Media OutReach Newswire - 19 June 2025 – Hong Kong Baptist University (HKBU) illuminated the path to global well-being as the Global Health Innovation Partner and sponsor of the Health and Wellbeing Track at the Times Higher Education (THE) Global Sustainable Development Congress (GSDC) 2025, from June 16-19, 2025. At this gathering of over 5,000 global thought leaders, HKBU presented its comprehensive, interdisciplinary strategy for health and well-being, spearheaded by its Health & Drug Discovery research aligned with the United Nations' Sustainable Development Goals, HKBU's vision for health transformation drives from data to actionable insight. It comprehensively integrates mental and digital well-being, real-time analytics, and innovative interdisciplinary approaches. This includes blending traditional Chinese Medicine with cutting-edge sciences like chemical biology and data analytics, complemented by advancements in environmental, physical, and social sciences.A highlight of HKBU's presence was the 6,000-square-foot "Well-being Zone", thoughtfully designed to embody the principle that health is holistic and interconnected. This innovative Zone brought the concept of interdisciplinarity to a global audience by seamlessly integrating diverse fields, from martial arts and mindfulness to cutting-edge digital health monitoring:Highlighting HKBU's research strength in the transformative power of technology for global health,, emphasised, "HKBU's recent top-50 global ranking in databases, design automation, and artificial intelligence underscores our collaborative ethos. By integrating advanced AI methodologies with clinical, pharmaceutical and social-science expertise, we are optimising diagnostics, accelerating drug discovery and enhancing surgical assistance. This interdisciplinary approach reinforces Hong Kong's reputation as a global hub for cutting-edge research and higher education.", highlighted HKBU's strategic edge, "Hong Kong is uniquely positioned to lead East–West integration in digital health and systems medicine. HKBU combines the rigour of life sciences with robust Chinese Medicine research, underpinned by advanced data analytics. This powerful synergy enables us to tackle complex health disparities at biological, social, and environmental levels, and build resilient, equitable health systems to meet future global challenges."In addition to numerous insightful presentations and the interactive experiences, HKBU Provost Professor Martin Wong gave a keynote at the session entitled "Reframing Sustainability through the Lens of Chinese Heritage and Innovation" convened by the China Education Association for International also released theReport ( in collaboration with Elsevier. This report examines the development and evolving research landscape of Chinese Medicine and its growing influence on modern #HKBU The issuer is solely responsible for the content of this announcement.
The Sun
a day ago
- Health
- The Sun
Hong Kong Baptist University and Elsevier Report Highlights Global Expansion of Chinese Medicine Research, Urges Standardised Frameworks for Broader Integration
ISTANBUL, TURKEY - Media OutReach Newswire - 18 June 2025 – The report 'Evolving Legacy: Decoding the Scientific Trajectory of Chinese Medicine' released today by Hong Kong Baptist University (HKBU) and Elsevier, reveals the growing impact of Chinese Medicine research on global healthcare and modern health challenges. In this context, 'Chinese Medicine research' encompasses not only clinical practice, but also basic and translational science, AI-driven systems medicine, and the network pharmacology of herbal formulas. This first bibliometric analysis of Chinese Medicine research from 2014 to 2023 highlights the field's rapid growth, interdisciplinarity, and societal impact on Digital Health and Systems Medicine. Key findings from the report include: · Rapid expansion: Chinese Medicine research grew at a 10.6% compound annual growth rate — more than double the global research average — nearly tripling output between 2014 and 2023. · High scholarly impact: 14.2% of Chinese Medicine papers ranked among the world's top 10% most-cited (global norm: 10%), with a field-weighted citation impact (FWCI) of 1.12. · Interdisciplinary breadth: Medicine dominates (61.9% of output), followed by Biochemistry, Genetics & Molecular Biology (33.1%) and Pharmacology (28.1%). Citing publications span diverse major domains — from Engineering to Materials Science. · Global collaboration hubs: Hong Kong SAR and Macao SAR exceed 80% cross-regional collaboration, above the 18% world average, and achieving FWCI >1.6 in cross-regional collaborative publications. · Emerging research foci: Top-published trending topics include 'Herbaceous Agent | Chinese Medicine | Network Pharmacology' and COVID-19 applications, reflecting integration of omics, AI and systems methods. · Societal resonance: 11.1% of research outputs were mentioned on social media and 2.9% cited in policy documents, reflecting growing public and policymaker interest. Bridging a global integration gap Chinese Medicine's mainstream integration lacks a global, transparent, evidence-based framework. To elevate its scientific profile, key strategies include developing internationally accepted clinical guidelines through expert consensus, enhancing trial reporting standards to improve research quality, and fostering interdisciplinary, cross-regional collaboration to drive innovation and systemic impact. ''Evolving Legacy' demonstrates how Chinese Medicine research has matured into a global, evidence-informed field,' said Professor Lyu Aiping, Vice-President (Research & Development), HKBU, and a leading expert in Chinese Medicine. 'We envision a future where data science and AI illuminate what Chinese Medicine research has long intimated, providing deeper insights into health classifications and compound interventions. The next frontier is using Chinese Medicine research to uncover insights possibly overlooked in Digital Health and Systems Medicine, strengthening their scientific foundation and impact.' 'This report offers unprecedented insights into Chinese Medicine's evolving scientific landscape,' added Basak Candemir, Business Development Director, Analytical and Data Services, Elsevier. 'It illuminates the growing global impact of Chinese Medicine research and its role in diversified healthcare solutions, making a vital step towards bridging traditional knowledge with modern validation for the benefit of global health.' The report was developed using Elsevier's bibliometric tools, Scopus and SciVal, based on a comprehensive dataset and case studies compiled in collaboration with HKBU Chinese Medicine research experts. The report can be accessed on
Yahoo
a day ago
- Business
- Yahoo
A Chinese herbal-medicine stock with no revenue has surged 60,000% this year. 5 things to know about the company's mysterious spike.
Regencell Bioscience has soared nearly 60,000% year-to-date despite the company having no revenue. The Chinese herbal medicine company says it has a proprietary formula that can help treat ADHD and autism. There are a handful of factors that can explain the stock's mysterious climb. Shares of a little-known Chinese herbal medicine company have surged this year, with a fresh rally seeing the price quadruple in less than a week. It's been a head-scratching move, since the company is unprofitable, and shares have moved on seemingly no news. Regencell Bioscience Holdings, a Hong Kong-based firm specializing in traditional Chinese medicine, saw its US-listed stock soar 398% over the first two days of the week. But that move pales in comparison to the year-to-date increase, which amounted to roughly 60,000% through Tuesday's close. This embedded content is not available in your region. The company, which offers a proprietary oral formula it says can help treat disorders like ADHD and autism, has not generated any revenue, according to a regulatory filing from October. Over the last two fiscal years, the company said it lost a combined $10.4 million. So, what on earth is going on with this stock? Here's what to know. Regencell, which trades under the ticker "RGC" on the Nasdaq, soared 283% on Monday after its 38-for-1 stock split went into effect. The company originally announced the stock split on June 2. While stock splits don't generate any value for the company — with overall market cap staying unchanged — they are often viewed as a bullish driver, since a lower per-share price can make a stock more appealing to retail investors. Regencell finished Monday with a market cap of $30 billion, which swelled further to $39 billion at Tuesday's close. That made it — at least temporarily — worth more than more well-known companies like Lululemon, Kraft Heinz, and Reddit. The rapid rise of Regencell stock was bound to catch the eye of the retail crowd, but even the enduringly bullish cohort is incredulous about what might be going on. Though Regencell is still less talked about than flagship stocks like Tesla and Apple, users on Reddit were quick to identify the surge this week, with some speculating that Regencell was the market's newest "meme stock." "Regencell is doing some weird stuff again," one user wrote on the subreddit r/shortsqueeze. "I'm trying to decide if I should pull out before a possible crash," another user, who said they were a longtime investor, said on the r/pennystocks subreddit. "I was gambling. Didn't have a clue what this company is," another user wrote on a separate thread on r/shortsqueeze about Regencell this month. "I've been watching it go the last two weeks and keep telling myself that it will crash as soon as I buy back in." Regencell stock was also surging around the time Robert F. Kennedy Jr. continued his anti-vaccine push, with the Health and Human Services Secretary removing all members of the Advisory Committee on Immunization Practices last week, an independent panel that helps shape vaccination policies in the US. Regencell says it has a proprietary Traditional Chinese Medicine formula, a liquid-based oral formula it says can help treat ADHD or Autism Spectrum Disorder. The formula, which is meant to be taken twice a day and aims to treat the "fundamental cause" of neurocognitive disorders, contains "only natural ingredients," the firm says. Its website lists various herbs with qualities that can help with blood circulation, digestion, "detoxication," and other functions. "We have not generated revenue from any TCM formulae candidates or applied for any regulatory approvals, nor have distribution capabilities or experience or any granted patents or pending patent applications and may never be profitable," the firm said in its October filing. The company only has a small number of shares available to trade, one factor that can explain the large swings in its stock. Out of its 500 million shares, just 30 million are available for public trading. That's a far lower percentage than the average for the more widely traded stocks that populate major indexes. Most of the company is owned by Regencell's CEO, Yat-Gai Au. He owned 86% of the company, or a $426 million stake in the first quarter, according to holdings data. His net worth has surged to as much as $33 billion this week, according to Bloomberg, vaulting him into the ranks of the world's richest people. Regencell's second-largest holder, Digital Mobile Venture, owned 7.6% of the company at the end of the first quarter, or around $37.5 million. RBC, BlackRock, and Morgan Stanley also owned miniscule amounts of the stock. Initial public offerings from Chinese or Hong Kong-based firms have been in the spotlight recently. A report from The Wall Street Journal this week said that more than 20 China-based companies and 17 Hong Kong-based companies that went public on the Nasdaq since 2020 have lost 50% of their value or more in a single trading day over the last two years. In 2022, the Financial Industry Regulatory Authority issued a warning about a "heightened threat of fraud" related to small-cap companies that had recently gone public on US exchanges. Many of the companies associated with fraud had operators based in China or broker-dealers based in Hong Kong, the regulator said. In many cases, the broker-dealers were allocated 90% or more of the public float, Finra said, meaning they held most of the IPO shares. The small remaining float leaves stocks vulnerable to market manipulation, it said, referring to such companies as "ramp-and-dump schemes." Read the original article on Business Insider Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
a day ago
- Health
- Associated Press
Hong Kong Baptist University and Elsevier Report Highlights Global Expansion of Chinese Medicine Research, Urges Standardised Frameworks for Broader Integration
ISTANBUL, TURKEY - Media OutReach Newswire - 18 June 2025 – The report 'Evolving Legacy: Decoding the Scientific Trajectory of Chinese Medicine' released today by Hong Kong Baptist University (HKBU) and Elsevier, reveals the growing impact of Chinese Medicine research on global healthcare and modern health challenges. In this context, 'Chinese Medicine research' encompasses not only clinical practice, but also basic and translational science, AI-driven systems medicine, and the network pharmacology of herbal formulas. This first bibliometric analysis of Chinese Medicine research from 2014 to 2023 highlights the field's rapid growth, interdisciplinarity, and societal impact on Digital Health and Systems Medicine. HKBU and Elsevier launched a new report 'Evolving Legacy: Decoding the Scientific Trajectory of Chinese Medicine', highlighting the growing global impact of Chinese Medicine research in diversified healthcare solutions. Key findings from the report include: Bridging a global integration gap Chinese Medicine's mainstream integration lacks a global, transparent, evidence-based framework. To elevate its scientific profile, key strategies include developing internationally accepted clinical guidelines through expert consensus, enhancing trial reporting standards to improve research quality, and fostering interdisciplinary, cross-regional collaboration to drive innovation and systemic impact. ''Evolving Legacy' demonstrates how Chinese Medicine research has matured into a global, evidence-informed field,' said Professor Lyu Aiping, Vice-President (Research & Development), HKBU, and a leading expert in Chinese Medicine. 'We envision a future where data science and AI illuminate what Chinese Medicine research has long intimated, providing deeper insights into health classifications and compound interventions. The next frontier is using Chinese Medicine research to uncover insights possibly overlooked in Digital Health and Systems Medicine, strengthening their scientific foundation and impact.' 'This report offers unprecedented insights into Chinese Medicine's evolving scientific landscape,' added Basak Candemir, Business Development Director, Analytical and Data Services, Elsevier. 'It illuminates the growing global impact of Chinese Medicine research and its role in diversified healthcare solutions, making a vital step towards bridging traditional knowledge with modern validation for the benefit of global health.' The report was developed using Elsevier's bibliometric tools, Scopus and SciVal, based on a comprehensive dataset and case studies compiled in collaboration with HKBU Chinese Medicine research experts. The report can be accessed on Hashtag: #HKBU The issuer is solely responsible for the content of this announcement.
Arabian Post
2 days ago
- Health
- Arabian Post
Hong Kong Baptist University and Elsevier Report Highlights Global Expansion of Chinese Medicine Research, Urges Standardised Frameworks for Broader Integration
HKBU and Elsevier launched a new report 'Evolving Legacy: Decoding the Scientific Trajectory of Chinese Medicine', highlighting the growing global impact of Chinese Medicine research in diversified healthcare solutions. ISTANBUL, TURKEY – Media OutReach Newswire – 18 June 2025 – The report 'Evolving Legacy: Decoding the Scientific Trajectory of Chinese Medicine' released today by Hong Kong Baptist University (HKBU) and Elsevier, reveals the growing impact of Chinese Medicine research on global healthcare and modern health challenges. In this context, 'Chinese Medicine research' encompasses not only clinical practice, but also basic and translational science, AI-driven systems medicine, and the network pharmacology of herbal formulas. This first bibliometric analysis of Chinese Medicine research from 2014 to 2023 highlights the field's rapid growth, interdisciplinarity, and societal impact on Digital Health and Systems Medicine. Key findings from the report include: Rapid expansion : Chinese Medicine research grew at a 10.6% compound annual growth rate — more than double the global research average — nearly tripling output between 2014 and 2023. : Chinese Medicine research grew at a 10.6% compound annual growth rate — more than double the global research average — nearly tripling output between 2014 and 2023. High scholarly impact : 14.2% of Chinese Medicine papers ranked among the world's top 10% most-cited (global norm: 10%), with a field-weighted citation impact (FWCI) of 1.12. : 14.2% of Chinese Medicine papers ranked among the world's top 10% most-cited (global norm: 10%), with a field-weighted citation impact (FWCI) of 1.12. Interdisciplinary breadth : Medicine dominates (61.9% of output), followed by Biochemistry, Genetics & Molecular Biology (33.1%) and Pharmacology (28.1%). Citing publications span diverse major domains — from Engineering to Materials Science. : Medicine dominates (61.9% of output), followed by Biochemistry, Genetics & Molecular Biology (33.1%) and Pharmacology (28.1%). Citing publications span diverse major domains — from Engineering to Materials Science. Global collaboration hubs : Hong Kong SAR and Macao SAR exceed 80% cross-regional collaboration, above the 18% world average, and achieving FWCI >1.6 in cross-regional collaborative publications. : Hong Kong SAR and Macao SAR exceed 80% cross-regional collaboration, above the 18% world average, and achieving FWCI >1.6 in cross-regional collaborative publications. Emerging research foci : Top-published trending topics include 'Herbaceous Agent | Chinese Medicine | Network Pharmacology' and COVID-19 applications, reflecting integration of omics, AI and systems methods. : Top-published trending topics include 'Herbaceous Agent | Chinese Medicine | Network Pharmacology' and COVID-19 applications, reflecting integration of omics, AI and systems methods. Societal resonance: 11.1% of research outputs were mentioned on social media and 2.9% cited in policy documents, reflecting growing public and policymaker interest. Bridging a global integration gap ADVERTISEMENT Chinese Medicine's mainstream integration lacks a global, transparent, evidence-based framework. To elevate its scientific profile, key strategies include developing internationally accepted clinical guidelines through expert consensus, enhancing trial reporting standards to improve research quality, and fostering interdisciplinary, cross-regional collaboration to drive innovation and systemic impact. ''Evolving Legacy' demonstrates how Chinese Medicine research has matured into a global, evidence-informed field,' said Professor Lyu Aiping, Vice-President (Research & Development), HKBU, and a leading expert in Chinese Medicine. 'We envision a future where data science and AI illuminate what Chinese Medicine research has long intimated, providing deeper insights into health classifications and compound interventions. The next frontier is using Chinese Medicine research to uncover insights possibly overlooked in Digital Health and Systems Medicine, strengthening their scientific foundation and impact.' 'This report offers unprecedented insights into Chinese Medicine's evolving scientific landscape,' added Basak Candemir, Business Development Director, Analytical and Data Services, Elsevier. 'It illuminates the growing global impact of Chinese Medicine research and its role in diversified healthcare solutions, making a vital step towards bridging traditional knowledge with modern validation for the benefit of global health.' The report was developed using Elsevier's bibliometric tools, Scopus and SciVal, based on a comprehensive dataset and case studies compiled in collaboration with HKBU Chinese Medicine research experts. The report can be accessed on Hashtag: #HKBU The issuer is solely responsible for the content of this announcement.
